Traffic Lights - Latest Updates

Last updated: 21/02/2017

Other updates on this site
Drug Name Classification Clinical Indication Comments
ADALIMUMAB Red Hidradenitis suppurativa

In line with NICE TA 392

AFLIBERCEPT (Eylea®) (UPDATED) Red Wet age related macular degeneration. Diabetic macular oedema. Macular oedema due to central retinal vein occlusion and branch retinal vein occlusion.

Use in line with NICE TA346
NICE TA294
NICE TA305
NICE TA409

ALIROCUMAB Subcutaneous Injection (Praluent®) (UPDATED) Red Primary hypercholesterolaemia

In line with NICE TA 393

ALPROSTADIL cream (Vitaros®) (UPDATED) Black Erectile dysfunction
AMITRIPTYLINE (NEW) Amber Simple Depressive illness in children and young people
APREMILAST (Otezla®) (NEW) Red Psoriasis

In line with NICE TA 419

APREMILAST (Otezla®) (UPDATED) Black Psoriatic arthritis

In line with NICE TA 372 

ATALUREN (NEW) Red Duchenne muscular dystrophy

In line with NICE HST3

BRIVARACETAM (NEW) Red Epilepsy (third line agent)
CERTOLIZUMAB PEGOL (UPDATED) Red Rheumatoid arthritis

In line with  NICE TA 375 and NICE TA 415

DOXEPIN (NEW) Amber Simple Depressive illness in children and young people
DULAGLUTIDE (UPDATED) Amber Simple Type 2 Diabetes

If prescriber has not received specific training.

DULAGLUTIDE (UPDATED) Green Conditional Type 2 diabetes

Conditional on prescriber being trained to select and train patients – use in conjunction with updated NICE Clinical Guideline.  Once a week preparation.

ELBASVIR-GRAZOPREVIR (NEW) Red Hepatitis C

In line with NICE TA 413

FLUVOXAMINE (NEW) Amber Simple Depressive illness in children and young people
IMIPRAMINE (NEW) Amber Simple Depressive illness in children and young people
IMIQUIMOD cream 5% (Aldara®) (NEW) Green Actinic keratoses

In line with Actinic Keratoses treatment pathway

INGENOL MEBUTATE GEL (Picato®) (UPDATED) Green Actinic keratosis (non hypertrophic)

Actinic Keratoses (AK) Treatment Pathway

NORTRIPTYLINE (NEW) Amber Simple Depressive illness in children and young people
SACUBITRIL / VALSARTAN (Entresto®) (UPDATED) Amber Full SCA Heart failure

Full SCA    Request form

SECUKINUMAB (UPDATED) Red Psoriasis. Ankylosing spondylitis.

Use in line with NICE TA350
NICE TA407

SULFASALAZINE (NEW) Red Inflammatory Bowel Disease in Paediatrics

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more